Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia

Diagnostic Microbiology and Infectious Disease
Mark S RouseRobin Patel

Abstract

Ceftobiprole (BAL9141) is an investigational cephalosporin active against methicillin- and vancomycin-resistant staphylococci administered as a water-soluble prodrug, ceftobiprole medocaril (BAL5788). Using an immunocompetent murine pneumonia model of Haemophilus influenzae, Enterobacter cloacae, or extended-spectrum beta-lactamase (ESBL) nonproducing or producing Klebsiella pneumoniae pneumonia, we compared results of treatment with ceftobiprole medocaril (71 mg/kg, sc, qid), ceftriaxone (50 mg/kg, im, bid), or cefepime (50 mg/kg, ip, q.i.d.). Results were expressed as median and 25th to 75th percentile log10 colony forming units per gram of lung tissue. Ceftobiprole, ceftriaxone, and cefepime were each more active than was no treatment and were equally active for treatment of experimental H. influenzae, E. cloacae, or ESBL-nonproducing K. pneumoniae pneumonia. For ESBL-producing K. pneumoniae, no differences were detected between no treatment and treatment with ceftobiprole, ceftriaxone, or cefepime. Ceftobiprole is active against H. influenzae, E. cloacae, and ESBL-nonproducing K. pneumoniae in an immunocompetent experimental murine pneumonia model.

References

Dec 4, 2002·The Journal of Antimicrobial Chemotherapy·Ronald N JonesDouglas J Biedenbach
Oct 18, 2003·The Journal of Antimicrobial Chemotherapy·Bulent BozdoganPeter C Appelbaum
Feb 6, 2004·Diagnostic Microbiology and Infectious Disease·Nicolas C IssaRobin Patel
Mar 30, 2004·Antimicrobial Agents and Chemotherapy·E Azoulay-DupuisS Shapiro
Jun 25, 2004·Antimicrobial Agents and Chemotherapy·Anne Schmitt-HoffmannPéter Kovács
Apr 28, 2005·Antimicrobial Agents and Chemotherapy·Klaudia KosowskaPeter C Appelbaum

❮ Previous
Next ❯

Citations

Jun 6, 2009·International Journal of Clinical Practice·R A SteinG M Ganea
Jun 27, 2007·Antimicrobial Agents and Chemotherapy·Anne Marie QueenanKaren Bush
Jan 1, 2010·Infection and Drug Resistance·César Bustos, Jose L Del Pozo
Jun 14, 2008·Clinical & Developmental Immunology·Natalia MiliotiErnesto Oviedo-Orta
Sep 9, 2009·Expert Review of Anti-infective Therapy·Patricia L Schirmer, Stanley C Deresinski
Jan 25, 2007·Expert Opinion on Investigational Drugs·Garyphallia Poulakou, Helen Giamarellou
Jun 17, 2009·Expert Opinion on Pharmacotherapy·Ali El Solh
Apr 4, 2008·Diagnostic Microbiology and Infectious Disease·Stanley C Deresinski
Apr 4, 2008·Diagnostic Microbiology and Infectious Disease·Thomas P LodiseRonald N Jones
Nov 18, 2015·Future Microbiology·Thomas W L Scheeren
Jul 4, 2007·The Journal of Antimicrobial Chemotherapy·Cesar A AriasBarbara E Murray
Nov 6, 2014·Jundishapur Journal of Microbiology·Fereshteh ShahcheraghiSeyed Mohsen Zahraei
Jan 30, 2015·Jundishapur Journal of Microbiology·Mojtaba MoosavianAmir Peymani
Mar 17, 2015·Jundishapur Journal of Microbiology·Ahmad Farajzadeh SheikhRaheleh Sheikhi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.